Unlock instant, AI-driven research and patent intelligence for your innovation.

Differentiation of human embryonic stem cells

A pluripotent stem cell and cell technology, applied in embryonic cells, non-embryonic pluripotent stem cells, artificial cell constructs, etc., can solve the problem of not completely simulating the developmental procedures of higher mammals

Active Publication Date: 2018-05-15
JANSSEN BIOTECH INC
View PDF19 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] However, mouse models of embryonic stem cell development may not fully mimic the developmental program in higher mammals such as humans

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Differentiation of human embryonic stem cells
  • Differentiation of human embryonic stem cells
  • Differentiation of human embryonic stem cells

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0098] The role of insulin in the differentiation of human pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage Use: cluster planting

[0099] Previous studies have shown that high concentrations of FBS are detrimental to definitive endoderm (DE) formation from embryonic stem cells. See, eg, D'Amour et al., Nature Biotechnology, 2005, where induction of definitive endoderm from human embryonic stem cells was significantly increased when the FBS concentration was reduced from 10% FBS to 0.5-2% FBS. Similar observations were reported where the addition of 25ng / ml IGF or 200ng / ml insulin to 2% FBS for ES cells cultured in MEF-CM (mouse embryonic fibroblast conditioned medium) reduced the rate of activin-A treatment. The subsequent SOX17 expression was reduced by about 70%. See McLean et al., Stem Cells 25:29-38, 2007.

[0100] The observed inhibitory effect may be due to the presence of insulin or IGF in FBS, which triggers ...

example 2

[0111] The role of insulin in the differentiation of human pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage Use: single cell planting

[0112] Human embryonic stem cell line H1 (p40-p52) cells were used as single cells at 100,000 cells / cm 2 planted at a density of (1:30 dilution) (BD Biosciences; Cat. No. 356231) coated dishes supplemented with 16ng / ml FGF2 (Cat. No. Y0503, Sigma, MO) in MEF-CM (Mouse Embryo Fibroblast Conditioned Medium). 72 hours after seeding, cultures were differentiated into definitive endoderm (DE) as follows:

[0113] a. Supplemented with 2% fatty acid-free BSA (Cat. No. 68700, Proliant, Iowa), 0.0025 g / ml sodium bicarbonate (Cat. No. S3187, Sigma, Missouri), 1X GlutaMax TM (Cat. No. 35050-079, Invitrogen, California) and 100ng / ml Activin A (Andy Biotech, Minnesota) plus 20ng / ml WNT-3a (Cat. No. 1324-WN-002, The MCDB-131 (Cat. No. 10372-019 of Andy Biotechnology Company of Minnesota) (Catalo...

example 3

[0121] Role of IGF in the differentiation of human pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage: single cell planting

[0122] Human embryonic stem cell line H1 (p40-p52) cells were used as single cells at 100,000 cells / cm 2 planted at a density of (1:30 dilution) (BD Biosciences; Cat. No. 356231) coated dishes supplemented with 16ng / ml FGF2 (Cat. No. Y0503, Sigma, MO) in MEF-CM (Mouse Embryo Fibroblast Conditioned Medium). 72 hours after seeding, cultures were differentiated into definitive endoderm (DE) as follows:

[0123] a. Supplemented with 2% fatty acid-free BSA (Cat. No. 68700, Proliant, Iowa), 0.0025 g / ml sodium bicarbonate (Cat. No. S3187, Sigma, Missouri), 1X GlutaMax TM (Cat. No. 35050-079, Invitrogen, California) and 100 ng / ml GDF-8 (Cat. No. 120-00, Andy Biotech, Minnesota) plus 2.5 μM GSK3B inhibitor 14-propa- 2-en-1-yl-3,5,7,14,17,23,27-heptaazatetracyclo[19.3.1.1~2,6~.1~8,12~]twenty seven-1( 2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides methods for promoting the differentiation of pluripotent stem cells into insulin-producing cells. In particular, the invention provides methods of producing a population of cells wherein greater than 85% of the cells in the population express markers characteristic of the definitive endoderm lineage.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Provisional Patent Application Serial No. 61 / 378,472, filed August 31, 2010, which is hereby incorporated by reference in its entirety for all purposes. technical field [0003] The present invention provides methods for promoting the differentiation of pluripotent stem cells into insulin-producing cells. In particular, the invention provides methods of producing a population of cells wherein greater than 85% of the cells in the population express markers characteristic of the definitive endoderm lineage. Background technique [0004] Advances in cell replacement therapy for type 1 diabetes and the scarcity of transplantable islets have focused attention on developing a source of insulin-producing cells or beta cells suitable for engraftment. One approach is to generate functional beta cells from pluripotent stem cells, such as embryonic stem cells. [0005] In vertebrate emb...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N5/0735C12N5/071C12N5/02
CPCC12N5/0678C12N2500/90C12N2501/105C12N2501/115C12N2501/16C12N2501/19C12N2501/33C12N2501/415C12N2501/727C12N2506/02C12N5/0676C12N5/00C12N5/0607C12N5/0613C12N5/0606C12N5/0608
Inventor A.雷扎尼亚
Owner JANSSEN BIOTECH INC